Reprogrammed Interchange Llc Sells 11,616 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold a total of 11,616 shares of Vor Biopharma stock at an average price of $30.05, amounting to approximately $349,060.80.
• Following the recent share sales, Reprogrammed Interchange LLC now owns 1,167,109 shares of Vor Biopharma, representing a 0.99% decrease in their ownership.
• Vor Biopharma stock has experienced a trading price drop, with shares down $1.66 to $27.77, amidst recent performance that includes a 1-year low of $2.62 and a high of $65.80.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business's stock in a transaction on Monday, October 20th. The shares were sold at an average price of $30.05, for a total transaction of $349,060.80. Following the sale, the insider directly owned 1,167,109 shares of the company's stock, valued at $35,071,625.45. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 21st, Reprogrammed Interchange Llc sold 200 shares of Vor Biopharma stock. The stock was sold at an average price of $30.07, for a total transaction of $6,014.00.
• On Friday, October 17th, Reprogrammed Interchange Llc sold 25,717 shares of Vor Biopharma stock. The stock was sold at an average price of $30.25, for a total transaction of $777,939.25.
• On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The stock was sold at an average price of $30.45, for a total transaction of $61,539.45.
• On Wednesday, October 15th, Reprogrammed Interchange Llc sold 71,655 shares of Vor Biopharma stock. The stock was sold at an average price of $31.92, for a total transaction of $2,287,227.60.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The stock was sold at an average price of $30.97, for a total transaction of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total transaction of $934,796.16.

Vor Biopharma Price Performance

NASDAQ:VOR traded down $1.66 during mid-day trading on Tuesday, reaching $27.77. The company's stock had a trading volume of 348,840 shares, compared to its average volume of 394,637. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The business's fifty day simple moving average is $36.24. The stock has a market capitalization of $190.22 million, a price-to-earnings ratio of -0.10 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Hedge Funds Weigh In On Vor Biopharma

Hedge funds have recently modified their holdings of the stock. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma during the first quarter valued at about $100,000. Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares during the period. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after buying an additional 26,535 shares during the period. Jane Street Group LLC acquired a new position in Vor Biopharma in the 1st quarter worth approximately $140,000. Finally, XTX Topco Ltd acquired a new position in Vor Biopharma in the 2nd quarter worth approximately $66,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on VOR shares. Wall Street Zen downgraded shares of Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Vor Biopharma in a report on Thursday, August 14th. Zacks Research downgraded shares of Vor Biopharma from a "hold" rating to a "strong sell" rating in a report on Monday, October 13th. Robert W. Baird upgraded shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and upped their price objective for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. Finally, Baird R W upgraded shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $77.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.